352 related articles for article (PubMed ID: 22913338)
1. Inhibition of osteoclastogenesis by RNA interference targeting RANK.
Ma R; Xu J; Dong B; Kauther MD; Jäger M; Wedemeyer C
BMC Musculoskelet Disord; 2012 Aug; 13():154. PubMed ID: 22913338
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of triptolide on titanium particle-induced osteolysis and receptor activator of nuclear factor-κB ligand-mediated osteoclast differentiation.
Kim JA; Ihn HJ; Park JY; Lim J; Hong JM; Kim SH; Kim SY; Shin HI; Park EK
Int Orthop; 2015 Jan; 39(1):173-82. PubMed ID: 25416122
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
[TBL] [Abstract][Full Text] [Related]
4. Cell adhesion signaling regulates RANK expression in osteoclast precursors.
Mochizuki A; Takami M; Miyamoto Y; Nakamaki T; Tomoyasu S; Kadono Y; Tanaka S; Inoue T; Kamijo R
PLoS One; 2012; 7(11):e48795. PubMed ID: 23139818
[TBL] [Abstract][Full Text] [Related]
5. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
6. Picroside II Inhibits RANKL-Mediated Osteoclastogenesis by Attenuating the NF-κB and MAPKs Signaling Pathway In Vitro and Prevents Bone Loss in Lipopolysaccharide Treatment Mice.
Yang X; Gao W; Wang B; Wang X; Guo H; Xiao Y; Kong L; Hao D
J Cell Biochem; 2017 Dec; 118(12):4479-4486. PubMed ID: 28464271
[TBL] [Abstract][Full Text] [Related]
7. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.
Jules J; Zhang P; Ashley JW; Wei S; Shi Z; Liu J; Michalek SM; Feng X
J Biol Chem; 2012 May; 287(19):15728-38. PubMed ID: 22416138
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of osteolysis and increase of bone formation after local administration of siRNA-targeting RANK in a polyethylene particle-induced osteolysis model.
Córdova LA; Trichet V; Escriou V; Rosset P; Amiaud J; Battaglia S; Charrier C; Berreur M; Brion R; Gouin F; Layrolle P; Passuti N; Heymann D
Acta Biomater; 2015 Feb; 13():150-8. PubMed ID: 25462844
[TBL] [Abstract][Full Text] [Related]
10. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
11. Bone Morphogenetic Protein-2 Promotes Osteoclasts-mediated Osteolysis via Smad1 and p65 Signaling Pathways.
Miao X; Yuan J; Wu J; Zheng J; Zheng W; Wang F; Wang C; Li X; Liu S; Shi Z; Li J
Spine (Phila Pa 1976); 2021 Feb; 46(4):E234-E242. PubMed ID: 33156278
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
Nagata N; Kitaura H; Yoshida N; Nakayama K
Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
[TBL] [Abstract][Full Text] [Related]
13. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
Evans CE; Mylchreest S; Andrew JG
BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
[TBL] [Abstract][Full Text] [Related]
14. Monocrotaline Suppresses RANKL-Induced Osteoclastogenesis In Vitro and Prevents LPS-Induced Bone Loss In Vivo.
Wei CM; Su YJ; Qin X; Ding JX; Liu Q; Song FM; Zong SH; Xu J; Zhou B; Zhao JM
Cell Physiol Biochem; 2018; 48(2):644-656. PubMed ID: 30025412
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
[TBL] [Abstract][Full Text] [Related]
16. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
[TBL] [Abstract][Full Text] [Related]
17. Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-{kappa}B and c-Fms.
Granholm S; Lundberg P; Lerner UH
J Endocrinol; 2007 Dec; 195(3):415-27. PubMed ID: 18000304
[TBL] [Abstract][Full Text] [Related]
18. Anti-IFN-γ Antibody Promotes Osteoclastogenesis in Human Bone Marrow Monocyte-Derived Macrophages Co-Cultured with Tuberculosis-Activated Th1 Cells.
Deng J; Sun D; Luo F; Zhang Q; Chen F; Xu J; Zhang Z
Cell Physiol Biochem; 2018; 49(4):1512-1522. PubMed ID: 30205409
[TBL] [Abstract][Full Text] [Related]
19. The effect of adenovirus-mediated siRNA targeting BMPR-II on UHMWPE-induced osteoclast formation.
Wang Y; Wu NN; Mu YQ; Zhang RX; Hu M; Li RD; Chen L; He BC; Deng ZL
Biomaterials; 2013 Jan; 34(1):150-9. PubMed ID: 23079666
[TBL] [Abstract][Full Text] [Related]
20. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption.
Kim MS; Day CJ; Selinger CI; Magno CL; Stephens SR; Morrison NA
J Biol Chem; 2006 Jan; 281(2):1274-85. PubMed ID: 16280328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
